ITC Travel Grant Winners

Trisha Cubb, MD
MD Anderson Cancer Center
MALIGNANT STRUMA OVARII (MSO) CLINICAL CHARACTERISTICS AND OUTCOMES: A RETROSPECTIVE TERTIARY CANCER CENTER EXPERIENCE

Aurelie Forget-Renaud, MD
University of Sherbrooke, Department of Medicine
B SYMPTOMS AND AN ENLARGED THYMUS – A RED HERRING EXPLAINED BY GRAVES’ DISEASE

Isabelle Fournier, MD, MSc, FRCSC
MD Anderson Cancer Center
PROGNOSTIC SIGNIFICANCE OF BRAFV600E STATUS IN PATIENTS DIAGNOSED WITH PAPILLARY THYROID CANCER (PTC)

Sara Hamidi, MD, FRCPC
MD Anderson Cancer Center
REAL-WORLD EXPERIENCE WITH LENVATINIB PLUS PEMBROLIZUMAB IN METASTATIC BRAF WILD-TYPE ANAPLASTIC THYROID CARCINOMA (BRAFWT-ATC)

Carolina Janovsky, MD, PhD
Federal University of Sao Paulo
ASSOCIATION OF THYROID PEROXIDASE ANTIBODIES AND CHRONIC KIDNEY DISEASE: ELSA-BRASIL COHORT STUDY

Catherine Jensen, MD
University of Wisconsin, Department of Surgery
BARRIERS AND FACILITATORS TO INTERVENTION STRATEGIES FOR DE-IMPLEMENTATION OF TOTAL THYROIDECTOMY FOR LOW-RISK THYROID CANCER

Sonam Kumari, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases, NIH
TARGETING PI3K/AKT/MTOR SIGNALING AND INHIBITION OF BCR/ABL TYROSINE KINASE AND GLUCOSE UPTAKE OVERCOMES RESISTANCE TO LENVATINIB IN THYROID CANCER

Mihaela Stefan-Lifshitz, PhD
Albert Einstein College of Medicine
PD-L1 ACTIVATES INTRINSIC CELLULAR FUNCTIONS IN THYROID CELLS: IMPLICATIONS FOR IMMUNE CHECKPOINT INHIBITOR INDUCED THYROIDITIS

Jennifer Rui Wang, MD
MD Anderson Cancer Center, Department of Head and Neck Surgery
A TUMOR-CELL SPECIFIC GENE SIGNATURE DERIVED FROM SINGLE-CELL SEQUENCING IS PROGNOSTIC ACROSS INDEPENDENT COHORTS OF PAPILLARY THYROID CARCINOMA PATIENTS

Steven Xie, MD
University of Michigan Hospitals
NON-CLINICAL FACTORS IN SURGICAL DECISION MAKING FOR LOW-RISK THYROID CANCER: WHAT’S CHANGED?

Thomas Szabo Yamashita, MD
Winship Cancer Institute of Emory University
Exposomic Analysis of Thyroid Cancer: Correlating histopathological characteristics with persistent environmental organic pollutants

Xiao Zhao, MD
MD Anderson Cancer Center
ANAPLASTIC THYROID CANCER UNDERGOES GENOMIC AND PHENOTYPIC PLASTICITY IN RESPONSE TO BRAF INHIBITOR TREATMENT